Biohaven Pharmaceutical News and Activities
Presence
Biohaven Pharmaceutical develops and sells medicines for neurological, immune, and rare diseases. Its products and research services support patients, healthcare providers, and partners in the pharmaceutical market.
Biohaven Pharmaceutical products and services overview:
- Neurology medicines
- Rare disease therapies
- Immunology treatments
- Clinical research
- Drug development
Revenue: ~$50 million
Employees: 450
Headquarters: New Haven, United States (USA)
Alphaton Capital is a company listed under the stock ticker PRTG (CA).
Alphaton Capital has a direct presence in 2 countries.
They are in:
- Software50%
- Pharmaceuticals50%
Acquisition, funding and merger involving Alphaton Capital.
- Alphaton Capital has just announced a $43 Million fundraising (posted on April 17 2026).
Executives
View the org chart displaying its 116 main executives
Most searched biographies at Biohaven Pharmaceutical
- Vlad Coric, Chief Executive Officer and Chairman of the Board
- John Childs, Director
- Bob Hugin, Director
Create your alert
to follow the executive moves at Biohaven Pharmaceutical.
Pharmaceuticals
Alphaton Capital has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Biohaven Pharmaceutical
- Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy | Biohaven, Ltd.
- Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile | Biohaven, Ltd.
- Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results | Biohaven, Ltd.
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment | Biohaven, Ltd.
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Biohaven, Ltd.
- Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference | Biohaven, Ltd.
- Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 | Biohaven, Ltd.
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder | Biohaven, Ltd.
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress | Biohaven, Ltd.
- Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M | Biohaven, Ltd.
- View more press releases Close
Social media about Biohaven Pharmaceutical
- Biohaven Pharmaceutical on Wikipedia, Google News & Yahoo Finance
- Biohaven Pharmaceutical on LinkedIn, X (Twitter) & YouTube
